PF PRISM CV Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PF PRISM CV, and when can generic versions of PF PRISM CV drugs launch?
PF PRISM CV has sixteen approved drugs.
There are twenty-nine US patents protecting PF PRISM CV drugs.
There are six hundred and fifteen patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.
Summary for PF PRISM CV
| International Patents: | 615 |
| US Patents: | 29 |
| Tradenames: | 11 |
| Ingredients: | 11 |
| NDAs: | 16 |
Drugs and US Patents for PF PRISM CV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-001 | Jan 27, 2012 | RX | Yes | No | 8,791,140*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Pf Prism Cv | TORISEL | temsirolimus | SOLUTION;INTRAVENOUS | 022088-001 | May 30, 2007 | AP | RX | Yes | Yes | 8,026,276*PED | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | RX | Yes | Yes | 10,869,924*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-002 | Sep 7, 2023 | RX | Yes | No | 7,858,643 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-002 | Sep 7, 2023 | RX | Yes | No | 8,785,632 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-001 | Sep 26, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PF PRISM CV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-003 | Feb 23, 2004 | 5,403,833*PED | ⤷ Sign Up |
| Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | 6,002,008 | ⤷ Sign Up |
| Pf Prism Cv | INLYTA | axitinib | TABLET;ORAL | 202324-002 | Jan 27, 2012 | 7,141,581 | ⤷ Sign Up |
| Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-002 | May 30, 2018 | 7,301,023 | ⤷ Sign Up |
| Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-002 | Aug 22, 2002 | 5,989,591*PED | ⤷ Sign Up |
| Pf Prism Cv | VFEND | voriconazole | TABLET;ORAL | 021266-002 | May 24, 2002 | 5,567,817 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PF PRISM CV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 50 mg and 100 mg | ➤ Subscribe | 2012-02-29 |
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-10 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Tablets | 100mg and 500mg | ➤ Subscribe | 2016-09-06 |
| ➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2008-09-12 |
| ➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2010-10-08 |
| ➤ Subscribe | Injection | 25 mg/mL, 1.8 mL vial | ➤ Subscribe | 2011-05-25 |
| ➤ Subscribe | Tablets | 0.5 mg | ➤ Subscribe | 2010-08-25 |
| ➤ Subscribe | Extended-release Tablets | 25 mg | ➤ Subscribe | 2015-05-08 |
| ➤ Subscribe | Tablets | 1 mg and 5 mg | ➤ Subscribe | 2018-02-23 |
| ➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2018-10-15 |
| ➤ Subscribe | Tablets | 50 mg and 200 mg | ➤ Subscribe | 2008-04-14 |
| ➤ Subscribe | For Injection | 50 mg per vial | ➤ Subscribe | 2009-06-15 |
| ➤ Subscribe | Tablets | 1 mg and 2 mg | ➤ Subscribe | 2009-12-17 |
International Patents for PF PRISM CV Drugs
Supplementary Protection Certificates for PF PRISM CV Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1218348 | C01218348/01 | Switzerland | ⤷ Sign Up | FORMER OWNER: AGOURON PHARMACEUTICALS, INC., US |
| 0440372 | 02C0030 | France | ⤷ Sign Up | PRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319 |
| 1786785 | PA2013005,C1786785 | Lithuania | ⤷ Sign Up | PRODUCT NAME: CRIZOTINIBUM; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004, 2 00121023 |
| 0648494 | SPC/GB01/037 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: SIROLIMUS; REGISTERED: CH IKS 55243 20000926; UK EU/1/01/171/001-005 20010313 |
| 1044189 | 08C0039 | France | ⤷ Sign Up | PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926 |
| 0401747 | SPC/GB01/036 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: SIROLIMUS; REGISTERED: CH IKS 55243 20000926; UK EU/1/01/171/001-005 20010313 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
